San Diego-based Pure Bioscience (NASDAQ: [[ticker:PURE]]) says it has raised up to $3 million by selling its stock and warrants to institutional investors in a direct offering. The net proceeds will be used for working capital. Pure, which has a line of antimicrobial products based on its proprietary silver dihydrogen citrate formula, announced plans in April to raise as much as $15 million.